This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Aprotinin
Description: Trasylol is a broad spectrum protease inhibitor obtained from bovine lung tissue. It inhibits multiple mediators (kallikrein, plasmin) of inflammation, fibrinolysis, and thrombin generation, thereby modulating the systemic inflammatory response seen with cardiopulmonary bypass surgery. Trasylol also inhibits trypsin and chymotrypsin, and to a lesser extent pronase P and papain.
Trasylol inhibits platelet activation by preventing proteolysis of the thrombin receptor protease activated receptor 1 (PAR-1). In granulocytes, it prevents the expression of pro-inflammatory adhesive glycoproteins.
Bayer and Nordic Group
In July 2012, Nordic Group announced that it has reached an agreement with Bayer HealthCare in which Nordic will acquire Trasylol (aprotinin injection) worldwide excluding the United States. Under this agreement, Nordic will become the Marketing Authorization Holder for aprotinin in the relevant Territories. Nordic will be managing global supplies of aprotinin in the relevant Territories.
Partners: Nordic Group BV
Pink Sheet BART Sends Bayer’s Trasylol Off The Market
Additional information available to subscribers only: